Investigational Drug Information for Pyrotinib
✉ Email this page to a colleague
What is the development status for investigational drug Pyrotinib?
Pyrotinib is an investigational drug.
There have been 136 clinical trials for Pyrotinib.
The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2021.
The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, and Brain Neoplasms. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Fudan University, and Henan Cancer Hospital.
There are six US patents protecting this investigational drug and ninety international patents.
Summary for Pyrotinib
| US Patents | 6 |
| International Patents | 90 |
| US Patent Applications | 30 |
| WIPO Patent Applications | 13 |
| Japanese Patent Applications | 5 |
| Clinical Trial Progress | Phase 1 (2021-07-01) |
| Vendors | 32 |
Recent Clinical Trials for Pyrotinib
| Title | Sponsor | Phase |
|---|---|---|
| RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Neoadjuvant Pyrotinib Versus Placebo Combined With Chemotherapy in HR-positive and HER2-low Early Breast Cancer | Jiangsu HengRui Medicine Co., Ltd. | Phase 3 |
| Neoadjuvant Pyrotinib Versus Placebo Combined With Chemotherapy in HR-positive and HER2-low Early Breast Cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 |
Clinical Trial Summary for Pyrotinib
Top disease conditions for Pyrotinib
Top clinical trial sponsors for Pyrotinib
US Patents for Pyrotinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Pyrotinib | ⤷ Sign Up | Method for preparing pharmaceutical composition comprising quinoline derivative or salt thereof | Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN) | ⤷ Sign Up |
| Pyrotinib | ⤷ Sign Up | Method for preparing tyrosine kinase inhibitor and derivative thereof | Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, Jiangsu, CN) | ⤷ Sign Up |
| Pyrotinib | ⤷ Sign Up | Method for preventing or treating tumor diseases with a combination of tyrosine kinase inhibitor and CDK4/6 inhibitor | JIANGSU HENGRUI MEDICINE CO., LTD. (Jiangsu, CN) SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (Shanghai, CN) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Pyrotinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Pyrotinib | Australia | AU2017211737 | 2036-01-27 | ⤷ Sign Up |
| Pyrotinib | Brazil | BR112018014544 | 2036-01-27 | ⤷ Sign Up |
| Pyrotinib | Canada | CA3008701 | 2036-01-27 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
